Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Meets Inverness' Rival Bid, Extends Offer to May 15

NEW YORK (GenomeWeb News) — Beckman Coulter has matched Inverness Medical Innovations’ offer to acquire Biosite, Biosite and Beckman said today.
 
As a result, Beckman and Biosite have signed a new agreement under which Beckman would buy Biosite for $90 a share, a per-share increase of $5 over the firm’s original bid.
 
The deal would now be worth an estimated $1.67 billion.
 
Biosite said last week it “intends” to accept a rival offer from Inverness, whose unsolicited bid raised the ante from $85 per share to $90 per share.
 
Biosite said that all “necessary regulatory clearances have been received,” and said it will provide more detailed information about the new agreement tomorrow.
 
Beckman Coulter has also extended the new offer until the end of the day on May 15. Under the terms of the amended agreement, Beckman is not obligated to extend the amended offer beyond that date, but retains the right to do so.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.